Repros Therapeutics Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

Phase 1
Completed
Conditions
Drug-drug Interaction
Interventions
Drug: Placebo
Drug: Androxal
First Posted Date
2013-11-25
Last Posted Date
2014-08-11
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
30
Registration Number
NCT01991327

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

First Posted Date
2013-11-25
Last Posted Date
2014-10-01
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
120
Registration Number
NCT01993225

Comparison of Two Formulations of Androxal

First Posted Date
2013-11-14
Last Posted Date
2019-05-06
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
16
Registration Number
NCT01984398
Locations
🇺🇸

Clinical Pharmacology of miami, Miami, Florida, United States

Open-Label Extension Study to ZPE-202

Phase 2
Withdrawn
Conditions
Endometriosis
Interventions
Drug: Proellex
First Posted Date
2013-10-14
Last Posted Date
2014-02-07
Lead Sponsor
Repros Therapeutics Inc.
Registration Number
NCT01961908

Comparison of Two Formulations of Proellex for Vaginal Administration

First Posted Date
2013-10-14
Last Posted Date
2014-01-24
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
8
Registration Number
NCT01962805

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Phase 1
Completed
Conditions
Tolerability
Pharmacokinetics
Interventions
Drug: Androxal
Drug: Placebo
First Posted Date
2013-10-10
Last Posted Date
2014-08-11
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
9
Registration Number
NCT01959685
Locations
🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Phase 1
Completed
Conditions
Secondary Hypogonadism
Interventions
Drug: Androxal 25 mg
First Posted Date
2013-08-16
Last Posted Date
2014-01-24
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
19
Registration Number
NCT01923870

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Phase 1
Completed
Conditions
Secondary Hypogonadism
Interventions
Drug: Androxal 25 mg
First Posted Date
2013-08-16
Last Posted Date
2014-08-11
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
26
Registration Number
NCT01923857

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Phase 3
Completed
Conditions
Secondary Hypogonadism
Interventions
Drug: Androxal
First Posted Date
2012-12-03
Last Posted Date
2014-04-16
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
300
Registration Number
NCT01739582

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Phase 2
Completed
Conditions
Uterine Fibroids
Interventions
Drug: Proellex 12 mg
Drug: Proellex 24 mg
First Posted Date
2012-12-03
Last Posted Date
2014-04-16
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
40
Registration Number
NCT01739621
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy